We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Sequenom Announces Launch of SensiGene Fetal(XY) - Fetal Sex Determination Test
News

Sequenom Announces Launch of SensiGene Fetal(XY) - Fetal Sex Determination Test

Sequenom Announces Launch of SensiGene Fetal(XY) - Fetal Sex Determination Test
News

Sequenom Announces Launch of SensiGene Fetal(XY) - Fetal Sex Determination Test

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Sequenom Announces Launch of SensiGene Fetal(XY) - Fetal Sex Determination Test"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Sequenom, Inc. has announced the launch of the SensiGene™ Fetal(XY) (Fetal Sex Determination) test by Sequenom's CAP accredited and CLIA-certified laboratory, Sequenom Center for Molecular Medicine (Sequenom CMM). This is the company's second laboratory developed test powered by its SEQureDx™ technology.

According to the Company, benefits of the SensiGene Fetal(XY) Fetal Sex Determination test include:

• Noninvasive and safe. The test requires only a simple blood sample from the mother.

• Early detection - first trimester fetal sex determination.

• Highly specific - allows the distinction between maternal and fetal DNA for both male and female fetuses.

• Physician-ordered.

"The launch of the SensiGene Fetal(XY) test represents another successful noninvasive prenatal test demonstrating the utility of using maternal blood to determine fetal status," said Lee P. Shulman, MD, Professor of Obstetrics and Gynecology and Chief of the Division of Clinical Genetics at the Feinberg School of Medicine at Northwestern University.

He continued, "This is a great leap forward in delivering a test with a high degree of accuracy, using cutting-edge technology which has been rigorously evaluated through blinded studies, performed in collaboration with internationally recognized prenatal diagnosticians. This test adds to the physicians' prenatal diagnostic arsenal by providing for safe and accurate noninvasive fetal testing."
Advertisement